CYP2B6 and tuberculosis: This is consistent with the typical two-week presentation caused by other drugs.[2,3] In the context of TB, it is more common to find non-immediate reactions, not only due to the number of medications the patient receives but also due to the genetic polymorphism of the ATDs-metabolizing enzymes with the presence of several human leukocyte antigen haplotypes and genetic variants.[23,24] Yu et al[25] determined the allelic frequencies of genes and found that (cytochrome P [CYP]) CYP2B6, CYP2E1, and NAT2 genes presented a higher risk of developing adverse drug events.